Short Interest Coverage: What’s Ahead for Ani Pharmaceuticals Incorporated (NASDAQ:ANIP) After Less Shorted Shares?

November 24, 2016 - By Darrin Black   ·   0 Comments

Short Interest Coverage: What’s Ahead for Ani Pharmaceuticals Incorporated (NASDAQ:ANIP) After Less Shorted Shares?

The stock of Ani Pharmaceuticals Incorporated (NASDAQ:ANIP) registered a decrease of 4.15% in short interest. ANIP’s total short interest was 864,200 shares in November as published by FINRA. Its down 4.15% from 901,600 shares, reported previously. With 139,100 shares average volume, it will take short sellers 6 days to cover their ANIP’s short positions. The short interest to Ani Pharmaceuticals Incorporated’s float is 12.24%. The stock increased 2.01% or $1.14 on November 23, hitting $57.96. About 86,081 shares traded hands. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has risen 20.15% since April 22, 2016 and is uptrending. It has outperformed by 14.74% the S&P500.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The company has a market cap of $661.93 million. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It has a 85.32 P/E ratio. The Company’s focused areas of product development include anti-cancer , hormones and steroids, and complex formulations.

Insitutional Activity: The institutional sentiment increased to 2.33 in 2016 Q2. Its up 0.82, from 1.51 in 2016Q1. The ratio improved, as 14 funds sold all ANI Pharmaceuticals Inc shares owned while 31 reduced positions. 28 funds bought stakes while 40 increased positions. They now own 5.41 million shares or 2.90% less from 5.57 million shares in 2016Q1.
Ny State Common Retirement Fund last reported 0% of its portfolio in the stock. Loomis Sayles And Ltd Partnership accumulated 103 shares or 0% of the stock. Tfs Cap Ltd Liability accumulated 12,559 shares or 0.13% of the stock. Ladenburg Thalmann Fincl Inc has 0% invested in the company for 302 shares. Nomura Holding holds 181,064 shares or 0.03% of its portfolio. Ativo Capital Management Limited Liability Company owns 16,605 shares or 0.23% of their US portfolio. Federated Investors Pa holds 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 8,064 shares. Oxford Asset Mngmt last reported 79,889 shares in the company. Moreover, Blackrock Advsr has 0% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 3,975 shares. Teachers Retirement Systems Of The State Of Kentucky owns 3,000 shares or 0% of their US portfolio. Aqr Mngmt Limited Liability Company, a Connecticut-based fund reported 12,126 shares. Panagora Asset Mgmt has 8,476 shares for 0% of their US portfolio. New York State Teachers Retirement holds 0% or 27,785 shares in its portfolio. Blackrock Fund Advsr holds 0.01% or 660,831 shares in its portfolio. Royal Fincl Bank Of Canada has 221 shares for 0% of their US portfolio.

Insider Transactions: Since August 8, 2016, the stock had 0 insider purchases, and 2 sales for $3.35 million net activity. PRZYBYL ARTHUR sold 37,455 shares worth $2.51M. 12,500 shares were sold by Schrepfer Robert W, worth $838,209 on Monday, August 8.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Out of 5 analysts covering ANI Pharma (NASDAQ:ANIP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. ANI Pharma has been the topic of 13 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Tuesday, May 24 by Standpoint Research. Raymond James initiated the stock with “Strong Buy” rating in Thursday, June 23 report. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Buy” rating by Standpoint Research on Friday, November 13. The rating was maintained by TH Capital with “Neutral” on Tuesday, August 4. On Wednesday, September 2 the stock rating was downgraded by TheStreet to “Buy”. Oppenheimer maintained the shares of ANIP in a report on Friday, July 31 with “Outperform” rating. Oppenheimer upgraded the stock to “Perform” rating in Tuesday, July 19 report. The rating was maintained by Oppenheimer on Friday, August 5 with “Outperform”. The stock has “Buy” rating given by TH Capital on Monday, September 28. The firm has “Buy” rating given on Monday, September 28 by Roth Capital.

ANIP Company Profile

ANI Pharmaceuticals, Inc. (ANI), incorporated on April 11, 2001, is an integrated specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. The Firm has approximately two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. The Company’s two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet. The facilities are specialized with various capabilities, enabling the Company to manufacture liquid, powder, and oral solid-dose products, topicals, controlled substances and products. It also performs contract manufacturing for other pharmaceutical companies.

More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: Prnewswire.com which released: “ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide …” on July 18, 2016, also Prnewswire.com with their article: “ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and …” published on October 27, 2016, Prnewswire.com published: “ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection …” on June 28, 2016. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: Prnewswire.com and their article: “ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full …” published on August 04, 2016 as well as Prnewswire.com‘s news article titled: “ANI Pharmaceuticals Reports Record Third Quarter Results and Year-To-Date 2016 …” with publication date: November 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>